RxDoctor Payments Data

Prashanth Vallabhanath, MD

Ophthalmic Plastic and Reconstructive Surgery · Portland, ORNPI 1386626372

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Amgen at 55.0% of the total.

$1,284in general payments, 2019–2025

Across 24 payments — averaging $53.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$707
  • Rxsight Inc$155
  • AbbVie$144
  • Alcon$137
  • Johnson & Johnson Surgical Vision, Inc.$110
  • Omeros Corporation$20
  • plus $12 from 1 others
$66,931in research payments, 2019–2025

Across 5 payments — averaging $13,386 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$67K

What the payments were for

  • Food & beverage$1,27099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)14$707
Rxsight Inc1$155
AbbVie(2 entities)2$144
Alcon3$137
Johnson & Johnson Surgical Vision, Inc.2$110
Omeros Corporation1$20
NEW World Medical,inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in Oregonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$286,806
Medicare patients
852
Services billed
2,760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine78$77,577
Cyclosporine24$13,122
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha520$6,197
ErythromycinErythromycin Base383$5,164
Latanoprost353$4,608
Brimonidine Tartrate51$2,326
Prednisolone Acetate29$1,660
Timolol Maleate100$1,072
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$910
Azithromycin78$356
Dorzolamide Hcl13$248
Prednisone21$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$144$77,57778 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few ophthalmic plastic and reconstructive surgery providers in Oregonon file to place this against a meaningful peer group, so we don't.

Other ophthalmic plastic and reconstructive surgery in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →